Research and references

Modafinil is one of the most studied wakefulness compounds in clinical pharmacology. The evidence base for its mechanism, safety profile, and off-label cognitive effects is public, peer-reviewed, and verifiable. This page is the reference index, primary sources for everything claimed on this site.

Clinical and regulatory documentation

• FDA Provigil prescribing information, original label, indications, dosage, full side-effect profile. accessdata.fda.gov
• EMA modafinil assessment, European Medicines Agency review of modafinil indications and safety. ema.europa.eu
• MHRA modafinil guidance (UK), Medicines and Healthcare products Regulatory Agency position on modafinil prescribing. gov.uk
• DEA Schedule IV listing (US), Drug Enforcement Administration classification and personal-use importation framework. deadiversion.usdoj.gov
• WHO essential medicines context, modafinil is not on the WHO essential medicines list, but the WHO maintains pharmacological monographs that document mechanism and dosing.

Mechanism and pharmacology (peer-reviewed)

• Mignot, E. et al. (1994), “Modafinil binds to the dopamine uptake carrier site with low affinity.” Sleep. The foundational pharmacology paper. PubMed 7973317
• Minzenberg & Carter (2008), “Modafinil: a review of neurochemical actions and effects on cognition.” Neuropsychopharmacology. Comprehensive mechanism review. PubMed 17914514
• Battleday & Brem (2015), “Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review.” European Neuropsychopharmacology. The off-label cognitive-enhancement systematic review. PubMed 26381811
• Wisor (2013), “Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions.” Frontiers in Neurology. The mechanism debate as of recent literature. PubMed 24109471

Safety profile (peer-reviewed)

• Roth et al. (2007), “Modafinil improves wakefulness and reduces sleepiness.” Long-term safety data across narcolepsy patients. PubMed 17561600
• Volkow et al. (2009), “Effects of modafinil on dopamine and dopamine transporters in the male human brain.” Dependence-potential analysis. PubMed 19293415
• Kumar (2008), “Approved and investigational uses of modafinil: an evidence-based review.” Drugs. Comprehensive indication and adverse-event review. PubMed 18840034
• Stevens-Johnson syndrome case reports, the rare-but-serious dermatological reaction discussed in razumna’s side-effect documentation. Documented in JAMA Dermatology and elsewhere; the rate is approximately one in a million users.

Modafinil vs armodafinil (the comparison literature)

• Darwish et al. (2009), “Pharmacokinetic profile of armodafinil in healthy subjects.” Side-by-side PK with modafinil. PubMed 19725664
• Lankford (2008), “Armodafinil: a new treatment for excessive sleepiness.” Expert Opinion on Investigational Drugs. Comparison framing.
• Tembe et al. (2011), “Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder.” Direct clinical comparison.

Community discussion (uncurated by razumna)

Vendor-independent community discussion happens in the venues below. Razumna does not run accounts there and does not curate what is said.

• r/Nootropics, largest English-language nootropics community on Reddit. Vendor self-promotion is restricted; the conversation is buyer-to-buyer. reddit.com/r/Nootropics
• r/ModafinilXL, vendor-discussion subreddit with a decade of buyer experience reports. Razumna appears in cross-vendor comparisons across the moda community. reddit.com/r/ModafinilXL
• r/modafinil, smaller, less vendor-focused. reddit.com/r/modafinil
• LongeCity nootropics forum, long-running enthusiast discussion, often surfaces protocols and side-effect notes not in clinical literature. longecity.org
• Examine.com modafinil page, independent evidence aggregator; not vendor-affiliated. examine.com/supplements/modafinil

How to use this page

Any claim on this site about modafinil, mechanism, half-life, side-effect profile, dosing, can be cross-referenced against the primary sources above. Razumna does not ask you to take the brand’s word for the pharmacology. The pharmacology is not the brand’s; it is published, peer-reviewed, and verifiable by anyone reading this.

What razumna IS asking you to evaluate is the operation: pricing, shipping, customs handling, refund posture. For that, the operational claims are backed by the first-dose guarantee and the customs replacement policy, policies razumna pays out under, not slogans.